Finepoint Capital LP Sage Therapeutics, Inc. Transaction History

Finepoint Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$40.65 - $59.54 $1.26 Million - $1.85 Million	-31,100 Reduced 8.0%	357,765 $16.8 Million
Q1 2023 May 12, 2023	BUY	$37.27 - $46.57 $264,617 - $330,647	7,100 Added 1.86%	388,865 $16.3 Million
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $1.53 Million - $2.07 Million	-47,548 Reduced 11.08%	381,765 $14.6 Million
Q3 2022 Nov 10, 2022	SELL	$32.28 - $43.27 $1.49 Million - $2 Million	-46,287 Reduced 9.73%	429,313 $16.8 Million
Q2 2022 Aug 12, 2022	BUY	$27.52 - $37.99 $13.1 Million - $18.1 Million	475,600 New	475,600 $15.4 Million

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

Stay updated on Finepoint Capital LP with notifications on news.